Adial Pharmaceuticals Inc ADIL

Healthcare Biotechnology

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients. AD04 is investigated in the Company’s ONWARD pivotal Phase III clinical trial for the treatment of AUD in subjects with certain target genotypes (estimated to be approximately one-third of the AUD population) identified using the Company’s companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.

NDAQ:ADIL - Post by User

Adial Pharmaceuticals Inc

Bullboard Posts

Next >>

Post by whytestockson Feb 28, 2024 10:15am

108 Views

Post# 35903673

Adial Pharmaceuticals Awarded New Patent from the United Sta

News; $ADIL Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office | BenzingaCHARLOTTESVILLE, Va., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)) ("Adial" or the "Company"), a clinical...ADIL - Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office | Benzinga

Bullboard Posts

Next >>

NervGen Pharma: Proof that NVG-291 works?